Focus on Lipids Care

Back to articles

Ezetimibe/simvastatin: Cancer risk not ruled out

KEY POINT

 

An analysis of three clinical trials involving more than 20,000 patients concludes that there is no convincing evidence supporting a link between ezetimibe/simvastatin (Vytorin—Merck; Schering-Plough) and cancer risk; however, some clinicians are not convinced and continue to express concern about the safety of the drug.

SOURCES

Rossebø AB et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.

Peto R et al. Analyses of cancer data from three ezetimibe trials [letter]. N Engl J Med. 2008;360:86–7.

Drazen JM et al. Ezetimibe and cancer: an uncertain association. N Engl J Med. 2008;359:1398–9.